*In breast cancer patients whose test results could impact treatment decisions (e.g., systemic treatment with PARP inhibitors for metastatic disease or adjuvant olaparib therapy for high-risk, HER2-negative breast cancer), BRCA testing should also be considered. This evidence concerns the gene ERBB2 and breast carcinoma.